Jeff Yass’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-38,545
| Closed | -$189K | – | 14444 |
|
|
2021
Q3 | $189K | Buy |
+38,545
| New | +$187K | ﹤0.01% | 11554 |
|
|
2021
Q1 | – | Sell |
-13,926
| Closed | -$72.7K | – | 13121 |
|
|
2020
Q4 | $60K | Buy |
+13,926
| New | +$59.6K | ﹤0.01% | 10703 |
|
|
2020
Q2 | – | Sell |
-17,276
| Closed | -$50.8K | – | 11303 |
|
|
2020
Q1 | $50K | Sell |
17,276
-45,947
| -73% | -$206K | ﹤0.01% | 9688 |
|
|
2019
Q4 | $240K | Buy |
63,223
+2,405
| +4% | +$11.5K | ﹤0.01% | 8433 |
|
|
2019
Q3 | $311K | Sell |
60,818
-38,177
| -39% | -$236K | ﹤0.01% | 8233 |
|
|
2019
Q2 | $614K | Buy |
98,995
+34,643
| +54% | +$199K | ﹤0.01% | 6836 |
|
|
2019
Q1 | $458K | Buy |
64,352
+16,693
| +35% | +$150K | ﹤0.01% | 6448 |
|
|
2018
Q4 | $407K | Buy |
+47,659
| New | +$620K | ﹤0.01% | 6412 |
|
|
2018
Q3 | – | Sell |
-11,876
| Closed | -$279K | – | 10598 |
|
|
2018
Q2 | $307K | Buy |
+11,876
| New | +$329K | ﹤0.01% | 7804 |
|
|
2018
Q1 | – | Sell |
-134,465
| Closed | -$4.24M | – | 10516 |
|
|
2017
Q4 | $4.56M | Sell |
134,465
-76,395
| -36% | -$2.13M | ﹤0.01% | 2642 |
|
|
2017
Q3 | $4.46M | Buy |
210,860
+184,388
| +697% | +$3.38M | ﹤0.01% | 2646 |
|
|
2017
Q2 | $463K | Buy |
+26,472
| New | +$438K | ﹤0.01% | 6792 |
|
|
2017
Q1 | – | Sell |
-29,028
| Closed | -$495K | – | 10357 |
|
|
2016
Q4 | $491K | Buy |
+29,028
| New | +$449K | ﹤0.01% | 7036 |
|
|
2016
Q1 | – | Sell |
-8,322
| Closed | -$236K | – | 9908 |
|
|
2015
Q4 | $236K | Buy |
+8,322
| New | +$140K | ﹤0.01% | 8148 |
|
Jeff Yass's ADMS Position: Q4 2021 in Review
Jeff Yass sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 38,545 shares — an estimated $189K sold.
Jeff Yass first reported a position in ADMS in Q4 2015 and held it in 14 quarters. The position peaked at $4.56M in Q4 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Jeff Yass reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Jeff Yass sold 38,545 Adamas Pharmaceuticals shares in Q4 2021, an estimated $189K.
- Jeff Yass first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 14 quarters.
- Jeff Yass's Adamas Pharmaceuticals position peaked at $4.56M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.